A Review of Multiple Venous Malformations of the Upper Limb: Classification, Genetics, and Pathogenesis

Mohammad M. Al-Qattan, MBBS

Summary: Venous (cavernous) malformations are commonly seen in the upper limb. There is no consensus in the literature regarding the classification of venous malformations. Patients may be viewed as 2 clinical entities: patients with single or multiple lesions. Single venous malformations are sporadic and nonsyndromic, whereas the presence of multiple malformations indicates the presence of either an inherited or an overgrowth (noninherited) disorder. In this article, the author reviews multiple venous malformations of the upper limb, offers a novel classification, and describes their clinical entities along with their genetics and pathogenesis. These clinical entities will also be described by categorizing the cases as per the clinical presentation. Furthermore, the number of cases seen by the author (during an experience of 28 years of practice in Saudi Arabia) in each category will be reviewed to give the reader an overall view of the frequency of presentation of each category to the hand/plastic surgery clinic. Clinically, patients may present in 4 different presentations depending on the distribution of the lesions: the late-onset malformations confined to the upper limb; malformations involving the limbs/face/trunk with no mucosal lesions; widespread malformations of the skin, oral mucosa, and the intestine; and venous malformations presenting as a well-known syndrome. The author has seen a total of 84 patients, and the most 2 common presentations were late-onset type (n = 26) and malformations involving the limbs/face/trunk with no mucosal lesions (n = 36). This is the most comprehensive review of multiple venous malformations of the upper limb. (Plast Reconstr Surg Glob Open 2021;9:e3391; doi: 10.1097/GOX.0000000000003391; Published online 26 January 2021.)

INTRODUCTION

Venous (cavernous) malformations are commonly seen in the upper limb. There is no consensus in the literature regarding the classification of venous malformations. Patients may be viewed as 2 clinical entities: patients with single or multiple lesions. Single venous malformations are sporadic and nonsyndromic, whereas the presence of multiple malformations indicates the presence of either an inherited or an overgrowth (noninherited) disorder. Inherited disorders are caused by germline mutations (the term “germline” mutation means that the mutation is present in all body cells) and there is usually a positive family history. Overgrowth noninherited disorders are caused by somatic mutations that only affect the involved tissues (the abnormal gene is present only in the pathological lesions), and family history is always negative.

METHODS

In this study, the author reviews multiple venous malformations of the upper limb, offers a novel classification, and describes their clinical entities along with their genetics and pathogenesis. These clinical entities will also be described by categorizing the cases as per the clinical presentation. Furthermore, the number of cases seen by the author (during an experience of 28 years of practice in Saudi Arabia) in each category will be reviewed to give the reader an overall view of the frequency of presentation of each category to the hand/plastic surgery clinic.

Disclosure: The author has no financial interest to declare in relation to the content of this article.
RESULTS

Classification

Our proposed classification of multiple venous malformation of the upper limb is shown in Table 1, and it divides this entity into 2 main groups: lesions associated with inherited disorders and those associated with overgrowth noninherited disorders.

The onset of presentation may be congenital or late-onset. Almost all venous malformations are congenital, being present at birth. They grow with the growth of the child; in some cases, the lesions are first noted early in childhood. Rarely, multiple venous malformations of the upper limb present late in childhood or in adolescence, and it is likely that the lesions were “subclinical” since birth. These lesions have been described as “acquired” malformations, but we believe that the term “late-onset” is more appropriate.

Decision for intervention to treat venous malformations is largely dependent on the severity of symptoms. Mild symptoms include the presence of the masses and the cosmetic concerns. Moderate symptoms include recurrent pain, which is usually related to thrombosis within the lesion (Fig. 1). Severe symptoms include those associated with nerve compression, muscle contracture, bone resorption, and consumption coagulopathy. Most of the reported cases of venous malformations in the literature were seen in relation to peripheral nerves, causing nerve compression. In these cases, the malformations arose from the vasa nervorum of the nerve, the venae comitantes of an adjacent artery, or an intramuscular vein. Congenital intramuscular venous malformations may initially present as asymptomatic masses, but may result in muscle contracture in adolescence. Untreated congenital venous malformations that are circumferential around the fingers may result in bone resorption and finger deformity (Fig. 2). Giant venous malformations of the proximal part of the upper limb may extend to the thoracic cavity and may be associated with consumption coagulopathy because of platelet trapping within the lesions.

Finally, venous malformations may either be superficial (within the skin and subcutaneous tissue) or deep (subfascial). Magnetic Resonance Imaging (MRI) also identifies the extent of the lesion and determines if the malformation is localized or diffuse. Localized lesions are usually treated surgically, whereas diffuse lesions are best treated by sclerotherapy (Fig. 1). However, sclerotherapy may also be used for localized venous malformations of the hand if the malformation is surrounding the neurovascular bundles and the intrinsic muscles. Sclerosants used to treat venous malformations include ethanol, sodium tetradecyl sulphate, polidocanol, and bleomycin.

Table 1. Classification of Multiple Venous Malformations of the Upper Limb

| The 2 Main Groups of Patients                      | Other Features                                           |
|---------------------------------------------------|----------------------------------------------------------|
| 1. Patients with inherited disorders (germline mutations) | Time of presentation: Congenital or late-onset          |
|                                                   | Symptoms: Mild, moderate, or severe                       |
|                                                   | Size of the lesion: Small (<3 cm), large (3–20 cm), or giant (>20 cm) |
| 2. Patients with noninherited overgrowth disorders (somatic mutations) | Depth of the lesion: Superficial or deep                  |
|                                                   | Localization of the lesion: Localized or diffuse          |

The Pathogenesis of Multiple Venous Malformations

Our review will demonstrate that all multiple venous malformations of the upper limb are related to the 2 main pathways controlling cellular proliferation: The Ras (RAS is a small GTPase) and the PI3K (Phosphatidyl Inositol 3-Kinase) pathways (Fig. 3). It is interesting to note that both pathways interact with each other because RAS is a direct stimulator of PI3K activity.
Fig. 2. Untreated congenital venous malformations of the hand. The circumferential lesions around the fingers resulted in bone resorption. A, Clinical appearance of the hand. B, X-ray showing the bone resorption around the untreated venous lesions.

Fig. 3. The Ras and PI3K pathways for cellular proliferation (see text for details).
The Ras Pathway (Fig. 3)

Stimulation of EGFR (Epidermal Growth Factor Receptor) results in the activation of Ras, Raf (Rapidly accelerated fibrosarcoma), MEK1/2 (MAPK/ERK Kinase 1/2), and finally, the activation of ERK1/2 (Extracellular Receptor Kinase), which is also known as MAPK (Mitogen Activated Protein Kinase). As shown in Figure 3, mutations of the RASA1 and the MAP3K3 genes are known to accelerate this pathway, leading to the development of multiple venous malformations of the upper limb.15,17

The PI3K Pathway (Fig. 3)

Stimulation of the Receptor Tyrosine Kinase will activate PI3K. PI3K is a heterodimer composed of a regulatory p85α subunit and a catalytic p110α subunit. The PIK3CA gene encodes the catalytic subunit. The activated PI3K will then participate in the activation of Akt1 (protein kinase B). Other proteins that participate in the activation of Akt1 include PDK1 (phosphoinositide-dependent Kinase 1) and m-TOR (mechanistic-target of rapamycin). Activating (gain-of-function) mutations of the TEK (which encodes the Tie-2 Receptor),18–21 AKT122, and PIK3CA22,23 genes, as well as loss-of-function mutations of the PTEN gene26 will accelerate this pathway, leading to the development of multiple venous malformations of the upper limb. Finally, somatic mutations of IDH1 and IDH2 genes (the genes encoding ISOCITRATE DEHYDROGENASE 1 and 2) will also lead to excessive activation of Akt1 (Fig. 3), resulting in multiple venous malformations seen in the Maffucci syndrome.25

Clinical Entities with Multiple Venous Malformations of the Upper Limb

Entities Caused by Germline Mutations (Table 2)

These entities are inherited and syndromic. Hence, the vascular lesions are seen not only in the limbs, but also in other sites such as the face, trunk, brain, and the gastrointestinal tract. Furthermore, a positive family history and characteristic features of the syndrome are encountered.

Familial multiple venous malformation syndrome (OMIM 600195) presents with multiple cutaneous and mucosal venous malformations. Cutaneous lesions usually involve the trunk and limbs. The syndrome is caused by germline mutations in the TEK gene (TYROSINE KINASE- ENDOTHELIAL). The gene encodes the Tie-2 Receptor (Tyrrosine-Protein Kinase Receptor Tie-2). The receptor is highly expressed in endothelial cells and is crucial for angiogenesis and vascular maintenance. The ligands for the Tie-2 receptor are the angiopoietins. When angiopoietins bind to the mutated receptor, there will be excessive activation of Akt1 protein and excessive cellular proliferation.18 The blue-rubber-bleb syndrome (OMIM 112200) has a phenotype similar to that of the familial multiple venous malformation syndrome and is also known to be caused by germline TEK mutations.23 However, the venous lesions of the blue-rubber-bleb syndrome are very characteristic: being deep blue in color and feels like rubbery blebs on palpation (Fig. 4).

Another syndrome that presents with multiple venous and intramuscular arteriovenous malformations of the upper limb is the Cowden syndrome (OMIM 158350). Other characteristic features of the syndrome include macrocephaly, facial skin lesions (multiple trichilemmomas are characteristic), gastrointestinal hamartomas, lipomas, and increased risk of developing cancer. The syndrome is caused by germline loss-of-function mutations of the PTEN gene. Loss-of-function of the encoded PTEN protein results in acceleration of cellular proliferation in the PI3K pathway.27 A Cowden-like syndrome (OMIM 615109) is caused by an activating mutation of the AKT1 gene, also leading to acceleration of the PI3K pathway.22

Another entity of multiple vascular lesions of the limb is the “capillary malformation – arteriovenous malformation 1” (OMIM 608354). The syndrome is an autosomal dominant disorder characterized by capillary, venous, and arteriovenous malformations of the limbs and face. The syndrome is caused by germline mutations of the RASA1 gene, which encodes a protein known as the p120-Ras-GAP protein (p120 Ras GTPase activating protein). Loss-of-function of the protein leads to acceleration of the Ras pathway of cellular proliferation.16

Table 2. Clinical Entities with Germline Mutations and Multiple Venous Malformations of the Upper Limb

| The Germline Gene Mutations | Name of Entity/Syndrome (OMIM number, if available) | Pathogenesis |
|----------------------------|-------------------------------------------------------|-------------|
| TEK gene                   | A) Familial multiple cutaneous and mucosal venous malformations syndrome (OMIM 600195) | The encoded Tie-2 receptor binds to angiopeoitin and is involved in the activation of the PI3K pathway |
|                            | B) Blue-Rubber-Bleb syndrome (OMIM 112200)            | Loss-of-function of the PTEN protein accelerates the PI3K pathway |
| PTEN gene                  | Cowden syndrome (also known as Bannayan-Riley syndrome) (OMIM 158350) | An activating mutation reading acceleration of the PI3K pathway |
| AKT1 gene                  | Cowden-like syndrome (OMIM 615109)                    | The encoded protein (p120-Ras-Gap) affects the Ras pathway |
| RASA1 gene                 | Capillary malformation: arteriovenous malformation 1 (OMIM 608354) | |
Spine abnormalities) is also caused by somatic PIK3CA mutations\(^2\) (Fig. 5). Al-Qattan\(^2\) described a syndrome of muscle overgrowth with the following characteristic features: the muscle overgrowth only affected the upper limbs and presented in a proximo-distal gradient (the hand being the most severely affected), mild hypoplasia of the index finger, hyperextension deformity of the metacarpophalangeal joint of the thumb, and ulnar deviation of the fingers. This syndrome has also been linked to somatic PIK3CA mutations.\(^2\) Rarely, this syndrome is associated with multiple venous malformations of the proximal part of the upper limb and adjacent trunk (Fig. 6). Another entity of multiple vascular lesions of the limb is the Klippel-Trenaunay-Parkes-Weber syndrome (KTPWS, OMIM 149000). The limb is enlarged with hypertrophy of soft tissues. Vascular lesions in the limb include capillary, venous, and arteriovenous malformations. These abnormalities are usually seen in 1 lower limb, but may also involve 1 upper limb (Fig. 7). About 25% of patients with KTPWS have somatic PIK3C mutations.\(^2\) This indicates locus heterogeneity (other gene mutations may cause the syndrome). One of these other genes linked to KTPWS is the AGGF1 gene encoding the AGGF1 (Angiogenic Factor with G-patch and FHA Domains 1) protein. Tissue biopsies from KTPWS patients show increased expression of the AGGF1 protein. This leads to an accelerated angiogenesis through the activation of the PI3K pathway because the AGGF1 protein is known to activate both the regulatory p85 \(\alpha\) and the catalytic p110 \(\alpha\) subunits of the PI3K protein\(^2\) (see Fig. 3). A specific somatic mutation of the MAP3K3 gene (C.1323 C>G, p.Iso441Met) is known to be associated with another type of venous malformation known as the “verrucous venous malformation or VVM.”\(^1\) VVM is nonhereditary, and the multiple venous malformations are seen in the skin of the limbs and trunk. There is no involvement of the deeper structures within the limbs or the internal organs. Lesions are seen at birth as small reddish-blue birth marks, which gradually enlarge and become raised, verrucous, and darker in color. Another specific mutation of the MAP3K3 gene (c.1723T>C, p.Tyr 575 His) within the veins of the upper limb is known to cause an entity known as the late-onset multiple venous malformation of the upper limbs.\(^4\) This entity has 3 unique features: the multiple venous malformations are usually first noted around adolescence, the lesions are always well localized (not diffuse), and they are confined to the upper limbs. The reason for confinement of these malformations to the upper limbs remains a mystery. The lesions may be subcutaneous or subfascial leading to mild nerve compression, and they vary in size from 1 to 20 cm\(^1\) (Fig. 8).

Somatic mutations of IDH1 and IDH2 genes are associated with the Ollier-Maffucci syndrome spectrum,\(^3\) which may

### Table 3. Clinical Entities with Somatic Mutations and Multiple Venous Malformations of the Upper Limb

| The Somatic Gene Mutations | Name of Entity/Syndrome (OMIM number, if available) | Pathogenesis |
|----------------------------|---------------------------------------------------|--------------|
| **TEK gene**               | a) A phenotype similar to the blue-rubber-bleb syndrome | The encoded Tie-2 receptor binds to angiopoietin and is involved in pathway |
|                            | b) Nonhereditary, nonsyndromic, multiple cutaneous venous malformations of the skin of the limbs and trunk | | |
| **PIK3CA gene**            | a) Nonhereditary, nonsyndromic, multiple cutaneous and mucosal venous malformations (limbs/trunk/mouth/intestine) | Activating the activation of the PI3K mutations leading to acceleration of the PI3K pathway in the affected tissues |
|                            | b) Nonhereditary syndrome: CLOVES syndrome (OMIM 612918) | | |
|                            | c) Nonhereditary syndrome: Upper limb muscle overgrowth-index finger hypoplasia syndrome. This syndrome may present with muscle overgrowth in 1 upper limb and venous malformations in the contralateral upper limb | | |
|                            | d) Nonhereditary syndrome: Klippel-Trenaunay-Parkes-Weber syndrome (OMIM 149000) | | |
| **MAP3K3 gene**            | a) Nonhereditary, nonsyndromic, multiple verrucous venous malformations of the limbs and trunk | An activating mutation leading to acceleration of the Ras pathway in the veins |
|                            | b) Nonhereditary, nonsyndromic, late-onset multiple venous malformations confined to the upper limbs | | |
| **IDH1 and IDH2 genes**    | Maffucci syndrome (OMIM 614569) | Mutations of the IDH1 and IDH2 genes activate the PI3K pathway |
be subclassified into 3 subtypes—Type I (Ollier syndrome): multiple enchondromas of the hands; Type II (Maffucci syndrome): multiple enchondromas and venous malformations of the hands/forearms; and Type III: A Maffucci phenotype with other vascular malformations seen outside the upper limb including the trunk and oral mucosa.31,32 Severe cases may end with amputation of the hand because of malignant transformation of the enchondromas (into chondrosarcoma) or disease progression, leading to a complete loss of function. The main function the IDH 1 and 2 protein enzymes is the conversion of isocitrate to 2-ketoglutarate. This reaction also produces NADPH (the reduced form of Nicotinamide Adenine Dinucleotide Phosphate), which is necessary for many cellular processes. The normal enzymatic activity within the cells also appears to be important in the homeostasis of the PI3K pathway.25 Hence, somatic mutations of IDH1 and IDH2 genes activate Akt1, explaining the multiple venous malformations in Types II and III of the Ollier-Maffucci spectrum.25 Some patients do not develop vascular lesions (Type I of the spectrum), and the reason for this remains to be unknown and requires further studies.

An Approach to the Diagnosis of the Various Clinical Entities Presenting with Multiple Venous Malformations of the Upper Limb

Clinically, patients presenting with multiple venous malformations of the upper limb should be examined for the presence of cutaneous or mucosal lesions outside the upper limbs, and should also be screened for any other congenital abnormalities.

As shown in Table 4, the clinical presentation may be categorized into 4 groups. If the venous malformations are confined to the upper limbs (ie, with no other cutaneous or mucosal lesions outside the upper limbs) with no other congenital defects, the most likely diagnosis is the nonhereditary late-onset type (MAP3K3 mutations). In the second category, the malformations are cutaneous/subcutaneous in the limbs/face/torso and there are no mucosal lesions. This entity may be related to RASA1 germ-line mutations, the classic venous malformations (classic lesions are compressible and develop phleboliths) caused by TEK somatic mutations, or the verrucous malformations caused by somatic MAP3K3 mutations. The third clinical category presents with widespread cutaneous and mucosal lesions and indicates a blue-rubber-bleb syndrome phenotype. Finally, the fourth category represents a well-known syndrome with characteristic features, including multiple venous malformations of the upper limbs. The author has seen a total of 84 patients; the most 2 common presentations were late-onset category with lesions confined to the upper limb (n = 26) and the widespread cutaneous lesions without involvement of the mucosa (n = 36) (Table 4).

**DISCUSSION**

This study specifically reviews the entity of multiple venous malformations of the upper limb. We could not find a similar review in the literature. As mentioned in the “Introduction” section, there has been no consensus regarding the classification of this entity; and our review offers such a classification (Table 1). The review
also identifies all clinical entities with multiple venous malformations of the upper limb (Tables 2 and 3). One interesting finding is the fact that all these clinical entities are linked to either germline or somatic mutations. Furthermore, all mutations are known to result in the acceleration of cellular proliferation within the affected veins through the activation of either the Ras or the PI3K pathways (Fig. 3). The review also offers an approach for the diagnosis of the various clinical entities presenting with multiple malformations of the upper limb (Table 4).

The current review is derived from Saudi Arabia. It is based on a review of the literature and the experience of the author over the last 28 years of practice in Saudi Arabia. It is important to realize that all clinical entities (Tables 2–4) are related to gene mutations. Therefore, there should be no differences in presentation for Saudi patients when compared with other ethnic groups.

Table 4 also shows the number of patients seen by the author in each clinical entity. Although this gives the reader an overall idea on the frequency of cases...
presenting to the hand/plastic surgery clinic, the numbers do not represent the prevalence of the entities in the general population. For example, Klippel-Trenaunay syndrome is a well-known syndrome that almost always affects the lower limb. Involvement of the upper limb is very rare, and the author has only encountered 2 cases over 28 years. Another example is Al-Qattan upper limb muscle overgrowth-index hypoplasia syndrome. The syndrome was described by the current author based on several cases.26,27 The syndrome is characterized by pure muscle overgrowth: usually without vascular lesions. Cases with concurrent vascular malformations are rare, and the author has only seen 1 case (Fig. 6). As seen in Table 4, the 2 most common clinical entities are the late-onset type (previously described by the author4,17) and patients presenting with widespread cutaneous lesions. The third category is uncommon and includes all patients with cutaneous and mucosal lesions. The gastrointestinal lesions may remain quiescent for a long time, presenting late with severe bleeding. Hence, one of the responsibilities of the plastic surgeon is to refer these patients to the gastroenterology service to rule out intestinal lesions. The last entity (Table 4) is relatively easy to diagnose from the clinical features of the syndrome, and most patients present with features of CLOVES syndrome.

As mentioned earlier, the 2 main modalities of management of venous malformations are surgery and sclerotherapy. Recurrence and the development of new lesions remain to be major problems with both modalities. Knowledge of the genetic basis of these lesions may have implications for investigating new therapeutic options.

The use of small molecule inhibitors of the pathways of cellular proliferation is now under trial in the management of cancer.33 The same concept has been applied for the medical management of overgrowth syndromes and vascular malformations of the upper limb. Proteus syndrome (OMIM 176920) is a progressive overgrowth syndrome characterized by asymmetric and disproportionate overgrowth of body parts, which is associated with connective tissue nevi and dysregulated adipose tissue. Marsh et al.34 reported on a child with Proteus syndrome and enlarging mediastinal and abdominal hamartomas resulting in tachypnea at rest, feeding problems, and the need for regular analgesics because of recurrent abdominal pain. The child was found to have a germline PTEN mutation with acceleration of the PI3K pathway. Medical treatment was done using oral rapamycin, which is an inhibitor of m-TOR in the PI3K pathway (see Fig. 3). All serious symptoms resolved, and there was reduction of mediastinal and abdominal hamartomas radiologically.
Another example is the case reported by Iacobas et al. A 6-year-old boy with Cowden syndrome and germline PTEN mutation (see Table 2) presented to the authors with symptomatic multiple venous and arteriovenous malformations of the hand and forearm. There was progressive loss-of-function of the hand, flexion contractures of the fingers, and significant pain. Sclerotherapy and embolization failed. Surgery resulted in recurrence and there was development of new lesions. The child was treated with oral rapamycin and this was effective to decrease the size of all vascular lesions, and a full range of motion of the hand was regained. The reduction in the size of the mutated venous malformations with the use of rapamycin has also been demonstrated experimentally in animal models. This suppressive effect on venous malformations will not only improve function and cosmesis of the upper limbs, but will also reduce the bleeding episodes of concurrent gastrointestinal venous malformations.

RAS inhibitors are also under trial in the management of tumors positive for somatic mutations along the Ras pathway. These inhibitors may be tried in severely symptomatic cases of multiple venous malformations of the upper limb if the identified gene mutation is along the Ras pathway.

Mohammad M. Al-Qattan
P.O. Box 18097
Riyadh 11415
Saudi Arabia
E-mail: mqoattan@hotmail.com

REFERENCES
1. Labow BI, Pike CM, Upton J. Overgrowth of the hand and upper extremity and associated syndromes. J Hand Surg Am. 2016;41:473–482.
2. Upton J, Coombs CJ, Mulliken JB, et al. Vascular malformations of the upper limb: a review of 270 patients. J Hand Surg Am. 1999;24:1019–1035.
3. Willard KJ, Cappel MA, Kozin SH, et al. Congenital and infantile skin lesions affecting the hand and upper extremity, part 1: vascular neoplasms and malformations. J Hand Surg Am. 2013;38:2271–2283.
4. Al-Qattan MM. Acquired localized subcutaneous cavernous vascular malformations of the hand. J Hand Surg Br. 2004;29:139–143.
5. Palmieri TJ. Vascular tumors of the hand and forearm. Hand Clin. 1987;3:225–240.
6. Al-Qattan MM, Al-Zahrani K, Al-Omawi M. The bifid median nerve revisited. J Hand Surg Eur Vol. 2009;34:212–214.
7. Dogramaci Y, Kalaci A, Sevne TT, et al. Intraneural hemangiomata of the median nerve: a case report. J Brachial Plex Peripher Nerve Inj. 2008;2:5–5.
8. Hariri A, Cohen G, Masmejean EH. Venous malformation involving median nerve causing acute carpal tunnel syndrome. J Hand Surg Eur Vol. 2011;36:431–432.
9. Kojima T, Ide Y, Marumo E, et al. Haemangioma of median nerve causing carpal tunnel syndrome. Hand. 1976;8:62–65.
10. Muchemwa FC, Ishihara T, Matsushita S. Intramuscular venous malformation in the upper arm with gross calcifications and compression of the ulnar nerve. Soud J Plast Reconstr Surg Hand Surg. 2007;41:93–95.
11. Pai V, Harp A, Pai V. Guyon’s canal syndrome: a rare case of venous malformation. J Hand Microsurg. 2009;1:115–115.
12. Parmar V, Haldeman C, Amadeuna S, et al. A vascular malformation presenting as a peripheral nerve sheath tumor. J Brachial Plex Peripher Nerve Inj. 2016;11:e38–e41.
13. Aronniemi J, Castrén E, Lappalainen K, et al. Sclerotherapy complications of peripheral venous malformations. Phlebolgy. 2011;31:712–722.
14. Castellano E, Doward J. RAS interaction with PTK3: more than just another effector pathway. Genes Cancer. 2011;2:261–274.
15. Couto JA, Vivero MP, Kozakewich HP, et al. A somatic MAP3K3 mutation is associated with verrucous venous malformation. Am J Hum Genet. 2015;96:480–486.
16. Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet. 2003;73:1240–1249.
17. Al-Qattan MM, Al-Balwi MA, Al-Zayed EM, et al. Late-onset multiple venous malformations confined to the upper limb: link to somatic MAP3K3 mutations. J Hand Surg Eur Vol. 2020;45:1025–1027.
18. Fukuharu S, Sako K, Minami T, et al. Differential function of Tie2 at cell–cell contacts and cell–substratum contacts regulated by angiopoietin-1. Nat Cell Biol. 2008;10:513–526.
19. Wang KL, Ma SF, Pang LY, et al. Sirolimus alternative to blood transfusion as a life saver in blue rubber bleb nevus syndrome: a case report. Medicine (Baltimore). 2018;97:e1453.
20. Soblet J, Kangas J, Nätynkki M, et al. Blue rubber bleb nevus (BRBN) syndrome caused by somatic TIE2 (TIE2) mutations. J Invest Dermatol. 2017;137:207–216.
21. Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TIE2 cause solitary and multiple sporadic venous malformations. Nat Genet. 2009;41:118–124.
22. Orloff MS, He X, Peterson C, et al. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet. 2013;92:76–80.
23. Limaye N, Kangas J, Mendola A, et al. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet. 2015;97:914–921.
24. Kurek KC, Luks VL, Ayturk UM, et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet. 2012;90:1108–1115.
25. Zhu H, Zhang Y, Chen J, et al. IDH1 R132H mutation enhances cell migration by activating AKT-mTOR signaling pathway, but sensitizes cells to 5-FU treatment as NADPH and GSH are reduced. PLoS One. 2017;12:e0169038.
26. Al-Qattan MM. Muscle overgrowth of the upper limb in a proximo-distal gradient and concurrent hypoplasia of the index finger. J Pediatr Orthop. 2014;34:715–719.
27. Al-Qattan MM, Hadadi A, Al-Thunayan AM, et al. Upper limb muscle overgrowth with hypoplasia of the index finger: a new over-growth syndrome caused by the somatic PIK3CA mutation c.3140A>G. BMC Med Genet. 2018;19:158.
28. Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015;166:1048–54.e1.
29. Zhang T, Yao Y, Wang J, et al. Haploinsufficiency of Klippel-Trenaunay syndrome gene Aggf1 inhibits developmental and pathological angiogenesis by inactivating PI3K and AKT and disrupts vascular integrity by activating VE-cadherin. Hum Mol Genet. 2016;25:5904–5110.
30. Arnary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011;43:1262–1265.
31. Cai Y, Wang R, Chen XM, et al. Maffucci syndrome with the spindle cell hemangiomas in the mucosa of the lower lip: a rare case report and literature review. J Cutan Pathol. 2013;40:661–666.
32. Desai S, Kubeyinje EP, Belagavi GS, et al. Maffucci’s syndrome. Ann Saudi Med. 1997;17:451–453.
33. Segerström L, Baryawno N, Sveinbjörnsson B, et al. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer. 2011;129:2958–2965.
34. Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008;5:357–361.

35. Iacobas I, Burrows PE, Adams DM, et al. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 2011;57:321–323.

36. Boscolo E, Limaye N, Huang L, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest. 2015;125:3491–3504.

37. O’Bryan JP. Pharmacological targeting of RAS: recent success with direct inhibitors. Pharmacol Res. 2019;139:503–511.